| Description |
NGB 2904 is an orally active and selective dopamine (DA) D3 receptor antagonist. NGB 2904 can be used for the research of cocaine addiction[1].
|
| Related Catalog |
|
| Target |
D3 Receptor
|
| In Vivo |
NGB 2904 (0.1~5 mg/kg; i.p.) significantly loweres the break-point for cocaine self-administration behavior reinforced under progressive-ratio conditions and significantly inhibits cocaine-triggered reinstatement of drug-seeking behavior in rats extinguished from daily cocaine self-administration[1]. NGB 2904 (0~10 mg/kg; i.p.) administered 30 min prior to the beginning of daily cocaine self-administration sessions has no significant effect on cocaine self-administration behavior at a unit cocaine reinforcement dose of 0.5 mg/kg/infusion compared to vehicle-treated animals. NGB 2904 (0.1 and 1 mg/kg) pretreatment significantly inhibits the enhanced brain stimulation reward produced by 2 mg/kg, but not by 10 mg/kg, of cocaine. NGB 2904 pretreatment produces a significant attenuation of this cocaine-triggered reinstatement of drug-seeking[1]. Animal Model: Male Long–Evans rats (250–300 g)[1] Dosage: 0.1~5 mg/kg Administration: I.p.; Result: Significantly lowered the break-point for cocaine self-administration behavior reinforced under progressive-ratio conditions and significantly inhibited cocaine-triggered reinstatement of drug-seeking behavior in rats extinguished from daily cocaine self-administration.
|
| References |
[1]. Xi ZX, et al. The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology. 2006;31(7):1393-1405.
|
